Field Trip Health (FTRP.C) closed a bought deal short form prospectus offering, pulling in $20,016,900 today, according to a press release.

The company issued 4,448,200 shares at a $4.50 price, along with warrants, exercisable at $5.60 but not until July 5, 2022. If the volume weighted average trading price goes over $9 for ten trading days, the company can push the expiry date with no less than 15 trading days notice.

“We are delighted to have the support of the investment community as we continue with our mission to increase access to psychedelic therapies both through the development of new drugs and products, and building the physical and digital infrastructure necessary to deliver these potentially life-transforming therapies. We believe that psychedelic drugs have significant potential in treating mental health disorders and we are committed to driving forward the psychedelic renaissance that is under way,” said Joseph del Moral, CEO of Field Trip.

Field Trip is only still a decently new company, having only been trading on the CSE since October. Since then they’ve seen highs in the $7 range, up from their starting point of $2.80. Right now they’re trading at $3.53 on respectable volume.

The warrants will be listed on the CSE under the symbol “FTRP.WT.” The money raised will be used for working capital, expansion, and research and development.

—Joseph Morton

Written By:

Joseph Morton

Joseph is a Vancouver-based author and journalist with both a communications degree and journalism diploma (and a few novels) under his belt. His joie de vivre is to spin difficult technical topics into more human-centric narratives. Buy him a coffee and he'll talk your ear off for hours about privacy issues, blockchain, cryptocurrency and martial arts. Don't talk to him if you're either a tomato, a bully, or if you're not a fan of either 1984 or Tender is the Night. No. You can still talk to him. Just be prepared to be told why you're wrong.

More By This Author
bought deal prospectus
Field Trip Health
0 0 votes
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x